BioSpace News Archive

XVIVO proudly announces the filing of an Investigational Device Exemption application to the US Food & Drug Administration.

Immuron Limited announced the sales results of its commercially available and over-the-counter gastrointestinal and digestive health immune supplement Travelan® for the third quarter of the fiscal year 2022, ending on March 31, 2022.

Surface Oncology announced that it will share a clinical update on SRF388 in an oral presentation at the American Society of Clinical Oncology 2022 Annual Meeting, to be held June 3-7, 2022 in Chicago, Il.

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2022, and provided an update on its clinical pipeline and other corporate developments.

Puma Biotechnology, Inc., a biopharmaceutical company, announced the release of titles of abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology Annual Meeting.

SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

Inspire Medical Systems, Inc. reported equity investments in two private companies, EnsoData, Inc. in Madison, WI, and Ognomy Inc. in Buffalo, NY.

Innoviva, Inc. reported financial results for the first quarter ended March 31, 2022.

Medicure Inc., a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reported its results from operations for the quarter and year ended December 31, 2021.

Ascentage Pharma announced that updated results from seven studies involving the company’s five novel drug candidates will be presented at the 2022 American Society of Clinical Oncology Annual Meeting.